tetano
Editor, Senior Moderator
Infection
. 2022 Jul 3.
doi: 10.1007/s15010-022-01869-w. Online ahead of print.
Clinical course of Coronavirus Disease-19 in patients with haematological malignancies is characterized by a longer time to respiratory deterioration compared to non-haematological ones: results from a case-control study
Oliva A[SUP] 1 [/SUP], Curtolo A[SUP] 2 [/SUP], Volpicelli L[SUP] 2 [/SUP], Cancelli F[SUP] 2 [/SUP], Borrazzo C[SUP] 3 [/SUP], Cogliati Dezza F[SUP] 2 [/SUP], Marcelli G[SUP] 4 [/SUP], Gavaruzzi F[SUP] 2 [/SUP], Di Bari S[SUP] 2 [/SUP], Ricci P[SUP] 4 [/SUP], Turriziani O[SUP] 5 [/SUP], Mastroianni Cm[SUP] 2 [/SUP], Venditti M[SUP] 2 [/SUP]
Affiliations
Abstract
Background: We evaluated clinical features and risk factors for mortality in patients with haematological malignancies and COVID-19.
Methods: Retrospective, case-control (1:3) study in hospitalized patients with COVID-19. Cases were patients with haematological malignancies and COVID-19, controls had COVID-19 without haematological malignancies. Patients were matched for sex, age and time of hospitalization.
Results: Overall, 66 cases and 198 controls were included in the study. Cases had higher prior corticosteroid use, infection rates, thrombocytopenia and neutropenia and more likely received corticosteroids and antibiotics than controls. Cases had higher respiratory deterioration than controls (78.7% vs 65.5%, p = 0.04). Notably, 29% of cases developed respiratory worsening > 10 days after hospital admission, compared to only 5% in controls. Intensive Care Unit admission and mortality were higher in cases than in controls (27% vs 8%, p = 0.002, and 35% vs 10%, p < 0.001). At multivariable analysis, having haematological malignancy [OR4.76, p < 0.001], chronic corticosteroid therapy [OR3.65, p = 0.004], prior infections [OR57.7, p = 0.006], thrombocytopenia [OR3.03, p < 0.001] and neutropenia [OR31.1, p = 0.001], low albumin levels [OR3.1, p = 0.001] and ≥ 10 days from hospital admission to respiratory worsening [OR3.3, p = 0.002] were independently associated with mortality. In cases, neutropenia [OR3.1, p < 0.001], prior infections [OR7.7, p < 0.001], ≥ 10 days to respiratory worsening [OR4.1, p < 0.001], multiple myeloma [OR1.5, p = 0.044], the variation of the CT lung score during hospitalization [OR2.6, p = 0.006] and active treatment [OR 4.4, p < 0.001] all were associated with a worse outcome.
Conclusion: An underlying haematological malignancy was associated with a worse clinical outcome in COVID-19 patients. A prolonged clinical monitoring is needed, since respiratory worsening may occur later during hospitalization.
Keywords: COVID-19; Haematological malignancy; Multiple myeloma; Non-Hodgkin lymphoma; SARS-CoV2.
. 2022 Jul 3.
doi: 10.1007/s15010-022-01869-w. Online ahead of print.
Clinical course of Coronavirus Disease-19 in patients with haematological malignancies is characterized by a longer time to respiratory deterioration compared to non-haematological ones: results from a case-control study
Oliva A[SUP] 1 [/SUP], Curtolo A[SUP] 2 [/SUP], Volpicelli L[SUP] 2 [/SUP], Cancelli F[SUP] 2 [/SUP], Borrazzo C[SUP] 3 [/SUP], Cogliati Dezza F[SUP] 2 [/SUP], Marcelli G[SUP] 4 [/SUP], Gavaruzzi F[SUP] 2 [/SUP], Di Bari S[SUP] 2 [/SUP], Ricci P[SUP] 4 [/SUP], Turriziani O[SUP] 5 [/SUP], Mastroianni Cm[SUP] 2 [/SUP], Venditti M[SUP] 2 [/SUP]
Affiliations
- PMID: 35781785
- DOI: 10.1007/s15010-022-01869-w
Abstract
Background: We evaluated clinical features and risk factors for mortality in patients with haematological malignancies and COVID-19.
Methods: Retrospective, case-control (1:3) study in hospitalized patients with COVID-19. Cases were patients with haematological malignancies and COVID-19, controls had COVID-19 without haematological malignancies. Patients were matched for sex, age and time of hospitalization.
Results: Overall, 66 cases and 198 controls were included in the study. Cases had higher prior corticosteroid use, infection rates, thrombocytopenia and neutropenia and more likely received corticosteroids and antibiotics than controls. Cases had higher respiratory deterioration than controls (78.7% vs 65.5%, p = 0.04). Notably, 29% of cases developed respiratory worsening > 10 days after hospital admission, compared to only 5% in controls. Intensive Care Unit admission and mortality were higher in cases than in controls (27% vs 8%, p = 0.002, and 35% vs 10%, p < 0.001). At multivariable analysis, having haematological malignancy [OR4.76, p < 0.001], chronic corticosteroid therapy [OR3.65, p = 0.004], prior infections [OR57.7, p = 0.006], thrombocytopenia [OR3.03, p < 0.001] and neutropenia [OR31.1, p = 0.001], low albumin levels [OR3.1, p = 0.001] and ≥ 10 days from hospital admission to respiratory worsening [OR3.3, p = 0.002] were independently associated with mortality. In cases, neutropenia [OR3.1, p < 0.001], prior infections [OR7.7, p < 0.001], ≥ 10 days to respiratory worsening [OR4.1, p < 0.001], multiple myeloma [OR1.5, p = 0.044], the variation of the CT lung score during hospitalization [OR2.6, p = 0.006] and active treatment [OR 4.4, p < 0.001] all were associated with a worse outcome.
Conclusion: An underlying haematological malignancy was associated with a worse clinical outcome in COVID-19 patients. A prolonged clinical monitoring is needed, since respiratory worsening may occur later during hospitalization.
Keywords: COVID-19; Haematological malignancy; Multiple myeloma; Non-Hodgkin lymphoma; SARS-CoV2.